Citations

Showing 10 of 108081 citations.

Nicotine lowers the secretion of the Alzheimer's amyloid β-protein precursor that contains amyloid β-peptide in rat
Utsuki, Tadanobu, Shoaib, Mohammed , Holloway, Harold W., Ingram, Donald K. , Wallace, William, Haroutunian, Vahram , Sambamurti, Kumar , Lahiri, Debomoy K. , Greig, Nigel H.

Mayo Clinic

Journal of Alzheimer's Disease | April 5, 2017 | Volume: 4 | Issue: 5 | Pages: 405-415

10.3233/jad-2002-4507 | PMID 12446972 Get It

The genetic causes of neurodegenerative diseases
Hardy, John , Hardy, John

Mayo Clinic

Journal of Alzheimer's Disease | April 5, 2017 | Volume: 3 | Issue: 1 | Pages: 109-116

10.3233/jad-2001-3115 | PMID 12214079 Get It

CAHPS Cancer Care Survey: Development, testing, and final content of a survey of patient experience with cancer care.
Evensen, Christian, Yost, Kathleen J. , Keller, San, Cowans, Tamika, Frentzel, Elizabeth , Jenkins, Sarah M. , Egginton, Jason S. , Arora, Neeraj, Garfinkel, Steven

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 35 | Issue: 8_suppl | Pages: 227-227

10.1200/jco.2017.35.8_suppl.227 Get It

227 Background: The objective of this work was to develop a reliable and valid survey measuring aspects of cancer care important to patients to be used in both inpatient and outpatient settings, and that allows comparisons of patient experiences across treatment centers and treatment modalities (medical oncology, radiation, surgery). Other objectives included testing various modes of data collection and developing a standardized sampling methodology based on ICD diagnosis and procedure codes. Methods: We conducted focus groups with patients who had received cancer treatment and with family members of cancer patients. We convened a panel of experts representing quality improvement, oncology, shared decision-making, patient safety, and patient advocacy to obtain feedback on the development of the survey. We interviewed stakeholder groups representing oncology associations to obtain feedback on focal provider, attribution and sampling. We then conducted a field test of the survey among six cancer centers around the country, conducted psychometric analyses, revised the survey, conducted a second field test among four community oncology practices in CA, re-analyzed the data, and finalized the survey. Results: Final survey content was determined using results of the formative research, psychometric analyses, and input from the CAHPS Consortium. The core survey includes 56 questions, 23 of which map to eight composites: Provider Communication, Enabling Patient Self-management, Team Available to Provide Information, Access to Care, Care Coordination, and Office Staff. Supplemental item sets include seven items assessing Shared Decision Making, four items measuring Keeping Patients Informed, and two additional Access to Care items. Mail-only, mail-telephone mixed-mode, and web-mail mixed-mode are recommended methods of data collection. The survey and all recruiting materials are available in English and Spanish. Conclusions: The CAHPS Cancer Care Survey is a rigorously developed, well-tested, reliable and valid survey of patient experiences with their cancer care. The survey and supporting materials are available free of charge on the CAHPS website (www.ahrq.gov/cahps).
Examining measurement properties of the consumer-based cancer care value index (CCCVI) survey: A measure to identify quality improvement priorities in cancer care.
Keller, San, Yost, Kathleen J. , Yang, Manshu

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 35 | Issue: 8_suppl | Pages: 222-222

10.1200/jco.2017.35.8_suppl.222 Get It

222 Background: Current approaches to measuring the quality of cancer care may not produce sufficient information to enable providers to structure care that aligns closely with their patients’ preferences. To close this gap, we developed the Consumer-based Cancer Care Value Index (CCCVI) survey, which assesses the aspects of cancer care that patients value the most and how their values align with their experience in receiving cancer care. Methods: The CCCVI field test included 721 adults who received cancer care in the last 12 months from 4 geographically diverse cancer care centers, including patients with varying stages of cancer, types of cancer, types of treatment (e.g., surgery, radiation, medical oncology), and demographic characteristics. The survey included items that asked patients to directly rate the “importance” of 24 aspects of cancer care, along with 24 corresponding items that measured the “frequency” with which they received each aspect of care. We evaluated the reliability and validity of the survey items, and developed “value grids” plots which visually depicted the “importance” scores against the “frequency” scores. We conducted subgroup analysis to examine income and racial/ethnic disparities in the extent of misalignment between patients’ values and experiences. Results: The survey demonstrated good internal consistency reliability (Cronbach’s alpha = 0.91) and acceptable-to-good construct and criterion validity. Value grids identified potential areas of improvement in the areas of how doctors communicate and how quickly patients get care. The subgroup analysis showed the most misalignments between patients’ values and experiences in the aspects of doctor communication for lower-income patients and in the aspects of getting care quickly for patients from racial/ethnic minority groups. Conclusions: The CCCVI survey is a reliable and valid tool for cancer care providers to identify top priority areas (i.e., high-importance but low-frequency areas) to facilitate their quality improvement efforts. It also recognizes subgroup variations in the misalignment between patients’ values and care experiences.
A cost-utility analysis of sentinel lymph node mapping, selective lymphadenectomy, and routing lymphadenectomy in the management of low-risk endometrial cancer.
Suidan, R.S., Mariani, Andrea , Soliman, Pamela T. , Sun, Charlotte C. , Cantor, Scott B. , Westin, Shannon N , Lu, Karen H. , Giordano, Sharon H. , Meyer, Larissa A.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 35 | Issue: 8_suppl | Pages: 10-10

10.1200/jco.2017.35.8_suppl.10 Get It

10 Background: Our objective was to evaluate the cost-utility of 3 lymphadenectomy (LND) strategies in the treatment of low-risk endometrial cancer (EC). Methods: A decision analysis model compared 3 LND strategies in women undergoing minimally invasive surgery (MIS) for EC: 1) routine LND in all pts; 2) selective LND based on intraoperative frozen section, in which 60% of pts undergo LND; and 3) sentinel lymph node mapping (SLN) based on a published algorithm, in which 15% of pts map unilaterally (requiring a contralateral LND) and 5% don’t map (requiring bilateral LND). Costs and outcomes were obtained from published literature and Medicare reimbursement rates. Costs categories consisted of hospital, physician, operating room, pathology, and lymphedema treatment. Effectiveness was defined as 3-year disease-specific survival adjusted for the impact of lymphedema (utility = 0.8) on quality of life. Incremental cost-effectiveness ratios (ICERs) per quality-adjusted life years (QALYs) gained were calculated. QALYs and costs were discounted at an annual 3% rate. Results: For the estimated 40,000 women undergoing surgery for low-risk EC each year in the US, the annual cost of routine LND, selective LND, and SLN is $722 million, $681 million, and $656 million respectively. In the base case scenario, routine LND had a cost of $18,041 and an effectiveness of 2.79 QALYs. Selective LND had a cost of $17,036 and an effectiveness of 2.81 QALYs, while SLN had a cost of $16,401 and an effectiveness of 2.87 QALYs. With a difference of $1,005 and 0.02 QALYs, selective LND was both less costly and more effective than routine LND, dominating it. However, with the lowest cost and highest effectiveness, SLN dominated the other modalities and was the most cost-effective strategy. No ICER could be determined. These findings were robust to multiple one- and two-way sensitivity analyses varying the rates of lymphedema and LND, surgical approach (open or MIS), lymphedema utility, and costs. Conclusions: Compared to routine and selective LND, SLN had the lowest cost and highest quality-adjusted survival, making it the most cost-effective strategy in the management of low-risk EC.
Intranuclear Actin Structure Modulates Mesenchymal Stem Cell Differentiation
Sen, Buer , Uzer, Gunes , Samsonraj, Rebekah M. , McGrath, Cody , Styner, Maya , Dudakovic, Amel , Wijnen, André J. van , Rubin, Janet , van Wijnen, Andre J, Xie, Zhihui , van Wijnen, Andre J , Styner, Maya , Sen, Buer

Mayo Clinic

Stem Cells | April 5, 2017 | Volume: 35 | Issue: 6 | Pages: 1624-1635

10.1002/stem.2617 | PMID 28371128 Get It

Abstract Actin structure contributes to physiologic events within the nucleus to control mesenchymal stromal cell (MSC) differentiation. Continuous cytochalasin D (Cyto D) disruption of the MSC actin cytoskeleton leads to osteogenic or adipogenic differentiation, both requiring mass transfer of actin into the nucleus. Cyto D remains extranuclear, thus intranuclear actin polymerization is potentiated by actin transfer: we asked whether actin structure affects differentiation. We show that secondary actin filament branching via the Arp2/3 complex is required for osteogenesis and that preventing actin branching stimulates adipogenesis, as shown by expression profiling of osteogenic and adipogenic biomarkers and unbiased RNA-seq analysis. Mechanistically, Cyto D activates osteoblast master regulators (e.g., Runx2, Sp7, Dlx5) and novel coregulated genes (e.g., Atoh8, Nr4a3, Slfn5). Formin-induced primary actin filament formation is critical for Arp2/3 complex recruitment: osteogenesis is prevented by silencing of the formin mDia1, but not its paralog mDia2. Furthermore, while inhibition of actin, branching is a potent adipogenic stimulus, silencing of either mDia1 or mDia2 blocks adipogenic gene expression. We propose that mDia1, which localizes in the cytoplasm of multipotential MSCs and traffics into the nucleus after cytoskeletal disruption, joins intranuclear mDia2 to facilitate primary filament formation before mediating subsequent branching via Arp2/3 complex recruitment. The resulting intranuclear branched actin network specifies osteogenic differentiation, while actin polymerization in the absence of Arp2/3 complex-mediated secondary branching causes adipogenic differentiation.
Cytologic features and clinical implications of undifferentiated carcinoma with osteoclastic giant cells of the pancreas: An analysis of 15 cases
Muraki, Takashi, HooKim, Kim, Memiş, Bahar , Graham, Rondell P. , Allende, Daniela , Shi, Jiaqi , Singh, Remmi, Baştürk, Olca , Adsay, Volkan , Reid, Michelle D. , Schaeffer, David F. , Graham, Rondell P , Adsay, N Volkan

Mayo Clinic

Cancer Cytopathology | April 5, 2017 | Volume: 125 | Issue: 7 | Pages: 563-575

10.1002/cncy.21859 | PMID 28371566 Get It

BACKGROUNDThe cytologic features of undifferentiated pancreatic carcinoma with osteoclastic giant cells (UOC) are rarely described.METHODSCytologic and clinicopathologic characteristics in 15 UOC fine‐needle aspiration (FNA) specimens were analyzed.RESULTSFNA specimens were obtained from 6 men and 8 women with a mean age of 65 years who had UOCs (head, n = 7; body, n = 3; and tail, n = 4) with a mean radiologic size 7.3 cm, and some had a cystic component (n = 9). Three cell types (osteoclastic giant cells, pleomorphic tumor giant cells, and spindled/histiocytoid cells) were observed in 12 of 15 specimens (80%); and pancreatic ductal adenocarcinoma (PDAC) was present in 11 specimens. FNA diagnoses were UOC (n = 6), PDAC (n = 5), poorly differentiated carcinoma (n = 2), “suspicious for neoplasm” (n = 1), and “negative” (n = 1). Five of 5 specimens with osteoclastic giant cells were positive for cluster of differentiation 68 (CD68) (a glycoprotein that binds to low‐density lipoprotein). Pleomorphic tumor giant cells and spindled/histiocytoid cells were positive for pancytokeratin (6 of 7 specimens), CAM5.2 (2 of 3 specimens), and epithelial membrane antigen (2 of 2 specimens). INI‐1 protein expression was retained in 3 of 3 specimens. The Ki‐67 labeling index was assessed in 3 specimens and was 12%, 18%, and 40%; 4 of 12 resected UOCs were pure, and 8 were mixed with PDAC. One resection specimen had intraductal papillary mucinous neoplasm, and 2 had mucinous cystic neoplasms. The median overall survival (OS) of patients who had UOCs identified on FNA was 8 months (6 died [OS, 8 months; range, 2‐22 months], and 8 remained alive [OS, 3 months; range, 1‐27 months]), which was similar to the survival of 74 patients who had PDACs identified on FNA (OS, 15 months; P = .279) but worse than that of the 27 patients with UOCs who did not undergo FNA (OS, 92 months; P = .0135).CONCLUSIONSThe 3 classical UOC cell types are identifiable on FNA, making cytologic diagnosis possible if considered in the differential. A PDAC component is often also observed. The survival advantage of UOC over pure PDAC appears to be negated by FNA and requires further investigation. Cancer Cytopathol 2017;125:563–75. © 2017 American Cancer Society.
Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation
Rivera, Christina G. , Narayanan, Prasanna P., Perissinotti, Anthony J. , Gedrimaite, Zivile, Han, Zhe , Steinbeck, Jennifer L, Pisano, Jennifer , Seo, Susan K. , Paskovaty, Alla , Pettit, Natasha N. , Miceli, Marisa H. , Hsu, Meier , Delacruz, Jennifer, Rivera, Christina G

Mayo Clinic

Journal of Antimicrobial Chemotherapy | April 5, 2017 | Volume: 72 | Issue: 8 | Pages: 2355-2358

10.1093/jac/dkx122 | PMID 28475803 Get It

Crowdsourcing seizure detection: algorithm development and validation on human implanted device recordings
Baldassano, Steven N. , Brinkmann, Benjamin H. , Ung, Hoameng , Blevins, Tyler, Conrad, Erin C. , Leyde, Kent, Cook, Mark , Khambhati, Ankit N. , Wagenaar, Joost , Litt, Brian , Worrell, Gregory A. , Brinkmann, Benjamin H , Cook, Mark J

Mayo Clinic

Brain | April 5, 2017 | Volume: 140 | Issue: 6 | Pages: 1680-1691

10.1093/brain/awx098 | PMID 28459961 Get It

Characterization of relative biological effectiveness for conventional radiation therapy: a comparison of clinical 6 MV X-rays and 137Cs
Howard, Michelle E. , Beltran, Chris , Herman, Michael , Sarkaria, Jann, Herman, Michael G., Sarkaria, Jann N. , Beltran, Chris J

Mayo Clinic

Journal of Radiation Research | April 5, 2017 | Volume: 58 | Issue: 5 | Pages: 608-613

10.1093/jrr/rrx018 | PMID 28444207 Get It

ABSTRACT Various types of radiation are utilized in the treatment of cancer. Equal physical doses of different radiation types do not always result in the same amount of biological damage. In order to account for these differences, a scaling factor known as the relative biological effectiveness (RBE) can be used. 137Cesium (137Cs) has been used as a source of radiation in a significant body of radiation therapy research. However, high-energy X-rays, such as 6 MV X-rays, are currently used clinically to treat patients. To date, there is a gap in the literature regarding the RBE comparison of these two types of radiation. Therefore, the purpose of this study was to investigate the RBE of 137Cs relative to that of 6 MV X-rays. To determine the RBE, five cell lines were irradiated [Chinese hamster ovary (CHO); human lung adenocarcinoma (A549); human glioma (U251); human glioma (T98); and human osteosarcoma (U2OS)] by both types of radiation and assessed for cell survival using a clonogenic assay. Three of the five cell lines resulted in RBE values of ~1.00 to within 11% for all survival fractions, showing the physical and biological dose for these two types of radiation were equivalent. The other two cell lines gave RBE values differing from 1.00 by up to 36%. In conclusion, the results show the range in biological effect seen between cell lines, and therefore cell type must be considered when characterizing RBE.